Biotica Technology Ltd. partnered a preclinical program targeting mTOR (mammalian target of rapamycin) in a potential $195 million deal with Wyeth Pharmaceuticals to develop compounds against multiple indications, including inflammatory diseases and cancer. (BioWorld Today) Read More
